Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.

Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, Jassem J, Medioni J, DeJonge M, Rudin C, Sawyer M, Khayat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, Brockstein B, DeGreve J, Baurain JF, Maki R, D'Adamo D, Dickson M, Undevia S, Geary D, Janisch L, Bedard PL, Abdul Razak AR, Kristeleit R, Vitfell-Rasmussen J, Walters I, Kaye SB, Schwartz G.

Eur J Cancer. 2019 Sep 12;120:132-139. doi: 10.1016/j.ejca.2019.07.024. [Epub ahead of print]

2.

Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials.

Gadalla R, Noamani B, MacLeod BL, Dickson RJ, Guo M, Xu W, Lukhele S, Elsaesser HJ, Razak ARA, Hirano N, McGaha TL, Wang B, Butler M, Guidos CJ, Ohashi PS, Siu LL, Brooks DG.

Front Oncol. 2019 May 17;9:415. doi: 10.3389/fonc.2019.00415. eCollection 2019.

3.

A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).

Veitch Z, Zer A, Loong H, Salah S, Masood M, Gupta A, Bradbury PA, Hogg D, Wong A, Kandel R, Charames GS, Abdul Razak AR.

Sci Rep. 2019 May 14;9(1):7390. doi: 10.1038/s41598-019-43222-6.

4.

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL.

Cancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006.

PMID:
31085175
5.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL.

J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0.

6.

Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.

Tan T, Rheaume M, Wang L, Chow H, Spreafico A, Hansen AR, Razak ARA, Siu LL, Bedard PL.

Oncologist. 2019 Jul;24(7):e518-e525. doi: 10.1634/theoncologist.2018-0808. Epub 2019 Mar 4.

PMID:
30833487
7.

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL.

Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1.

8.

Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.

Shepshelovich D, McDonald K, Spreafico A, Razak ARA, Bedard PL, Siu LL, Minasian L, Hansen AR.

Oncologist. 2019 Apr;24(4):e146-e148. doi: 10.1634/theoncologist.2018-0332. Epub 2019 Feb 6.

PMID:
30728278
9.

Primary cardiac sarcomas: A multi-national retrospective review.

Chen TW, Loong HH, Srikanthan A, Zer A, Barua R, Butany J, Cusimano RJ, Liang YC, Chang CH, Iakobishvili Z, Razak ARA, Lewin J.

Cancer Med. 2019 Jan;8(1):104-110. doi: 10.1002/cam4.1897. Epub 2018 Dec 21.

10.

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK.

J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.

PMID:
30557521
11.

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A.

Eur J Cancer. 2019 Jan;107:1-7. doi: 10.1016/j.ejca.2018.10.017. Epub 2018 Dec 7.

PMID:
30529898
12.

Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma.

Lewin J, Davidson S, Anderson ND, Lau BY, Kelly J, Tabori U, Salah S, Butler MO, Aung KL, Shlien A, Dickson BC, Abdul Razak AR.

Cancer Immunol Res. 2018 Sep;6(9):1001-1007. doi: 10.1158/2326-6066.CIR-18-0037. Epub 2018 Jul 17.

13.

Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.

Bernstein LJ, Pond GR, Gan HK, Tirona K, Chan KK, Hope A, Kim J, Chen EX, Siu LL, Razak ARA.

Head Neck. 2018 Sep;40(9):2029-2042. doi: 10.1002/hed.25198. Epub 2018 Apr 17.

PMID:
29667262
14.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, Dotti K, Santoro A, Cohen RB, Gould M, Saraf S, Stein K, Han SW.

PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.

15.

Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis.

Zer A, Prince RM, Amir E, Abdul Razak AR.

Cancer Treat Rev. 2018 Feb;63:71-78. doi: 10.1016/j.ctrv.2017.12.003. Epub 2017 Dec 6. Review.

PMID:
29253836
16.

Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database.

Shepshelovich D, Goldvaser H, Wang L, Abdul Razak AR.

Invest New Drugs. 2018 Oct;36(5):933-938. doi: 10.1007/s10637-017-0549-6. Epub 2017 Dec 13. Review.

PMID:
29234946
17.

Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer.

Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O'Sullivan B, Waldron J, Goldstein DP, Weinreb I, Hope AJ, Kim JJ, Chan KKW, Chan AK, Siu LL, Bernstein LJ.

JAMA Otolaryngol Head Neck Surg. 2018 Jan 1;144(1):71-79. doi: 10.1001/jamaoto.2017.2235.

18.

Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.

Shepshelovich D, Goldvaser H, Wang L, Abdul Razak AR, Bedard PL.

Invest New Drugs. 2017 Dec;35(6):827-833. doi: 10.1007/s10637-017-0510-8. Epub 2017 Sep 14. Review.

PMID:
28905282
19.

Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.

Lewin J, Garg S, Lau BY, Dickson BC, Traub F, Gokgoz N, Griffin AM, Ferguson PC, Andrulis IL, Sim HW, Kamel-Reid S, Stockley TL, Siu LL, Wunder JS, Razak ARA.

Int J Cancer. 2018 Jan 1;142(1):57-65. doi: 10.1002/ijc.31039. Epub 2017 Oct 9.

20.

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A.

J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.

PMID:
28678668
21.

Survival outcomes for cutaneous angiosarcoma of the scalp versus face.

Bernstein JM, Irish JC, Brown DH, Goldstein D, Chung P, Razak ARA, Catton C, Gilbert RW, Gullane PJ, O'Sullivan B.

Head Neck. 2017 Jun;39(6):1205-1211. doi: 10.1002/hed.24747. Epub 2017 Apr 11.

PMID:
28398688
22.

Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs.

Bugano DDG, Hess K, Jardim DLF, Zer A, Meric-Bernstam F, Siu LL, Razak ARA, Hong DS.

Clin Cancer Res. 2017 Aug 1;23(15):4020-4026. doi: 10.1158/1078-0432.CCR-16-2354. Epub 2017 Apr 4.

23.

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.

Juergens RA, Bratman SV, Tsao MS, Laurie SA, Sara Kuruvilla M, Razak AR, Hansen AR.

Cancer Treat Rev. 2017 Mar;54:43-57. doi: 10.1016/j.ctrv.2017.01.003. Epub 2017 Jan 17. Review.

PMID:
28192747
24.

Determinants of the recommended phase 2 dose of molecular targeted agents.

Hansen AR, Cook N, Amir E, Siu LL, Abdul Razak AR.

Cancer. 2017 Apr 15;123(8):1409-1415. doi: 10.1002/cncr.30579. Epub 2017 Feb 9.

25.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

26.

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.

Chen Y, Camacho SC, Silvers TR, Razak AR, Gabrail NY, Gerecitano JF, Kalir E, Pereira E, Evans BR, Ramus SJ, Huang F, Priedigkeit N, Rodriguez E, Donovan M, Khan F, Kalir T, Sebra R, Uzilov A, Chen R, Sinha R, Halpert R, Billaud JN, Shacham S, McCauley D, Landesman Y, Rashal T, Kauffman M, Mirza MR, Mau-Sørensen M, Dottino P, Martignetti JA.

Clin Cancer Res. 2017 Mar 15;23(6):1552-1563. doi: 10.1158/1078-0432.CCR-16-1333. Epub 2016 Sep 20.

27.

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, Freshwater T, Shumway S, Liang LW, Oza AM, Schellens JH, Shapiro GI.

J Clin Oncol. 2016 Dec 20;34(36):4371-4380. doi: 10.1200/JCO.2016.67.5991. Epub 2016 Oct 31.

PMID:
27601554
28.

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR.

J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25. Erratum in: J Clin Oncol. 2017 Mar;35(7):812.

29.

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.

Grilley-Olson JE, Bedard PL, Fasolo A, Cornfeld M, Cartee L, Razak AR, Stayner LA, Wu Y, Greenwood R, Singh R, Lee CB, Bendell J, Burris HA, Del Conte G, Sessa C, Infante JR.

Invest New Drugs. 2016 Dec;34(6):740-749. Epub 2016 Jul 23.

PMID:
27450049
30.

Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).

Prawira A, Brana-Garcia I, Spreafico A, Hope A, Waldron J, Razak AR, Chen EX, Jang R, O'Sullivan B, Giuliani M, Bayley A, Cho J, Wang L, Perez-Ordonez B, Weinreb I, Siu LL, Hansen AR.

Invest New Drugs. 2016 Oct;34(5):575-83. doi: 10.1007/s10637-016-0367-2. Epub 2016 Jun 11.

PMID:
27289242
31.

Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.

Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS.

Eur J Cancer. 2016 May;59:1-12. doi: 10.1016/j.ejca.2016.01.006. Epub 2016 Mar 15.

PMID:
26990281
32.

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A.

J Clin Oncol. 2016 Dec;34(34):4142-4150. Epub 2016 Oct 31.

33.

Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.

Angarita FA, Cannell AJ, Abdul Razak AR, Dickson BC, Blackstein ME.

BMC Cancer. 2016 Jan 19;16:30. doi: 10.1186/s12885-016-2054-2.

34.

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE.

Ann Oncol. 2016 Feb;27(2):318-23. doi: 10.1093/annonc/mdv537. Epub 2015 Nov 23.

35.

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL.

Clin Cancer Res. 2016 Mar 15;22(6):1348-55. doi: 10.1158/1078-0432.CCR-15-1221. Epub 2015 Oct 21.

36.

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.

Marous M, Bièche I, Paoletti X, Alt M, Razak AR, Stathis A, Kamal M, Le Tourneau C.

Ann Oncol. 2015 Dec;26(12):2419-28. doi: 10.1093/annonc/mdv378. Epub 2015 Sep 14. Review.

PMID:
26371283
37.

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, Pandya SS, Bedard PL, Pierce KJ, Houk B, Roberts WG, Shreeve SM, Shapiro GI.

Invest New Drugs. 2015 Oct;33(5):1100-7. doi: 10.1007/s10637-015-0282-y. Epub 2015 Sep 4.

PMID:
26334219
38.
39.

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.

Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR.

Ann Oncol. 2015 Sep;26(9):1824-9. doi: 10.1093/annonc/mdv182. Epub 2015 Apr 17. Review.

PMID:
25888611
40.

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G.

Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17.

41.

A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.

Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, Douglas S, Wang L, Siu LL, Tannock IF, Bedard PL.

Invest New Drugs. 2014 Dec;32(6):1269-77. doi: 10.1007/s10637-014-0159-5. Epub 2014 Sep 12.

PMID:
25213162
42.

Early phase clinical trials to identify optimal dosing and safety.

Cook N, Hansen AR, Siu LL, Abdul Razak AR.

Mol Oncol. 2015 May;9(5):997-1007. doi: 10.1016/j.molonc.2014.07.025. Epub 2014 Aug 14. Review.

43.

Genomic testing in cancer: patient knowledge, attitudes, and expectations.

Blanchette PS, Spreafico A, Miller FA, Chan K, Bytautas J, Kang S, Bedard PL, Eisen A, Potanina L, Holland J, Kamel-Reid S, McPherson JD, Razak AR, Siu LL.

Cancer. 2014 Oct 1;120(19):3066-73. doi: 10.1002/cncr.28807. Epub 2014 Jun 24.

44.

Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.

Loong HH, Winquist E, Waldron J, Chen EX, Kim J, Palma D, Read N, Razak AR, Diaz-Padilla I, Chan K, Bayley A, Hossain M, Wang L, Chin S, Siu LL, Hope A.

Eur J Cancer. 2014 Sep;50(13):2263-70. doi: 10.1016/j.ejca.2014.05.021. Epub 2014 Jun 19.

PMID:
24953566
45.

Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.

Tan DS, Bedard PL, Kuruvilla J, Siu LL, Razak AR.

Cancer Discov. 2014 May;4(5):527-37. doi: 10.1158/2159-8290.CD-13-1005. Epub 2014 Apr 17. Review.

46.

Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

Manji A, Brana I, Amir E, Tomlinson G, Tannock IF, Bedard PL, Oza A, Siu LL, Razak AR.

J Clin Oncol. 2013 Nov 20;31(33):4260-7. doi: 10.1200/JCO.2012.47.4957. Epub 2013 Oct 14. Review.

PMID:
24127441
47.

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).

Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ.

Br J Cancer. 2013 Aug 20;109(4):943-9. doi: 10.1038/bjc.2013.380. Epub 2013 Jul 18.

48.

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E.

Invest New Drugs. 2014 Apr;32(2):243-9. doi: 10.1007/s10637-013-9965-4. Epub 2013 May 5.

49.

Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.

Le Tourneau C, Gan HK, Razak AR, Paoletti X.

PLoS One. 2012;7(12):e51039. doi: 10.1371/journal.pone.0051039. Epub 2012 Dec 12.

50.

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.

Abdul Razak AR, Soulières D, Laurie SA, Hotte SJ, Singh S, Winquist E, Chia S, Le Tourneau C, Nguyen-Tan PF, Chen EX, Chan KK, Wang T, Giri N, Mormont C, Quinn S, Siu LL.

Ann Oncol. 2013 Mar;24(3):761-9. doi: 10.1093/annonc/mds503. Epub 2012 Oct 28.

PMID:
23108949

Supplemental Content

Loading ...
Support Center